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The role of allogeneic blood or marrow transplantation (alloBMT) for peripheral T cell lymphoma (PTCL)
remains to be deﬁned. There is growing interest in reduced-intensity conditioning (RIC) regimens and/or
utilization of human leukocyte antigen haploidentical (haplo) grafts given concerns about treatment-
associated toxicities and donor availability. We reviewed the outcomes of 44 consecutive, related donor
alloBMTs for PTCL performed at Johns Hopkins Hospital from 1994 to 2011, including 18 RIC/haplo alloBMTs.
Patients receiving RIC (n ¼ 24) were older, with median age of 59 years (range, 24 to 70), than patients
receiving myeloablative conditioning (MAC, n ¼ 20), with median age of 46 years (range, 18 to 64), P ¼ .01. The
median age at RIC/haplo alloBMT was 60 years. The estimated 2-year progression-free survival (PFS) was 40%
(95% conﬁdence interval [CI], 26% to 55%) and overall survival (OS) was 43% (95% CI, 28% to 59%). In older
patients (60, n ¼ 14), the estimated 2-year PFS and OS were 38% (95% CI, 18% to 79%) and 45% (95% CI, 24% to
86%), respectively. On unadjusted analysis, there was a tendency toward superior outcomes for alloBMT in
ﬁrst remission versus beyond ﬁrst remission, with an estimated 2-year PFS of 53% (95% CI, 33% to 77%) versus
29% (95% CI, 9% to 45%), P ¼ .08. On competing risk analysis, the 1-year cumulative incidence of relapse was
38% for MAC/HLA-identical alloBMTs and 34% for RIC/haplo alloBMTs. Estimated 1-year nonrelapse mortality
was 10% for MAC and 8% for RIC (11% for RIC/haplo alloBMT). On unadjusted landmark analysis, patients with
acute grade II-IV or chronic graft-versus-host disease (GVHD) had a 17% probability of relapse (95% CI, 0% to
39%), compared with 66% (95% CI, 48% to 84%) in patients without GVHD, P ¼ .04. Utilization of RIC and
alternative donors expands treatment options in PTCL to those who are older and unable to tolerate high-dose
conditioning, with outcomes comparable with approaches using myeloablative regimens and HLA-matched
donors. AlloBMT may be appropriate in ﬁrst remission in select high-risk cases.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION METHODS
Peripheral T cell lymphomas (PTCLs) have variable
responses to chemotherapy and often relapse, even after
high-dose therapy with autologous stem cell rescue [1-4].
Thus, there is growing interest in allogeneic blood or marrow
transplantation (alloBMT) as an alternative given its potential
for a graft-versus-lymphoma (GVL) effect [5-9]. Older patient
age, difﬁculty identifying human leukocyte antigen (HLA)-
identical donors, and concerns about transplant-related
toxicities have limited the exploration of this approach. Yet,
recent advances in alloBMT platforms, including high-dose
post-transplantation cyclophosphamide for graft-versus-
host disease (GVHD) prophylaxis, have signiﬁcantly reduced
the morbidity of alloBMT, including HLA-haploidentical
(haplo) alloBMT [10,11]. Herein, we report the Johns Hop-
kins Hospital outcomes of related donor alloBMT for PTCL,
half of which used haplo grafts.edgments on page 606.
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After institutional review board approval, the Johns Hopkins BMT
registry was screened for diagnoses of PTCL or natural killer (NK) cell
lymphoma. Forty-four consecutive alloBMTs for PTCL in adults were iden-
tiﬁed from January 1994 to June 2011 and selected for analysis. Diagnostic
pathology was centrally reviewed before alloBMT. For the purposes of this
article, histologic diagnoses were designated using the 2008 World Health
Organization classiﬁcation of mature T cell and NK cell neoplasms [12].
International Prognostic Index or Prognostic Index for T cell lymphoma
scores could not be tabulated for many of the patients due to missing data
from the time of PTCL diagnosis and are thus not available for this alloBMT
cohort.
The presence of high-risk disease features as well as a strong institu-
tional research focus on alternative donor transplantation factored into
decisions regarding autologous BMT versus alloBMT, with 80% of patients in
this cohort enrolled in an alloBMTclinical trial. The decision to take a patient
to alloBMT in ﬁrst remission was dependent on the treating physician and
was based in part on the patient’s candidacy for myeloablative conditioning
(MAC), with in reduced-intensity conditioning (RIC)/haplo alloBMT priori-
tized over autologous BMT for those unable to tolerate MAC.
Transplantation
MAC regimens included Bu/Cy (busulfan pharmacokinetically dosed in
16 doses over 4 days to achieve an area under the curve of 800 to 1400
mmol min/L and cyclophosphamide 50 mg/kg i.v. daily for 4 days), Cy/TBI
(cyclophosphamide 50 mg/kg i.v. daily for 4 days and 1200 cGy total body
irradiation given as 300 cGy per day for 4 days), or Bu/Flu (busulfan phar-
macokinetically dosed as above and ﬂudarabine 40 mg/mm i.v. daily for 4
days). RIC regimens were ﬂudarabine-based, either Flu/Cy/TBI (ﬂudarabineTransplantation.
Table 1
Patient Characteristics
Characteristic Result
Age at alloBMT, yr, median (range) 51 (18-70)
MAC 46 (18-64)
RIC 59 (24-70)
Male sex, n (%) 24 (55)
Histology, n (%)
Nodal 23 (52)
PTCL, not otherwise speciﬁed 7
Angioimmunoblastic T cell lymphoma 6
Anaplastic large cell lymphoma, ALK negative 5
J.A. Kanakry et al. / Biol Blood Marrow Transplant 19 (2013) 602e606 60330 mg/mm i.v. daily for 5 days, cyclophosphamide 14.5 mg/kg i.v. daily for
2 days, and 200 cGy TBI) or Flu/TBI. Supportive care measures were
according to Johns Hopkins Hospital institutional standards.
Through 2006, cyclosporine was used for GVHD prophylaxis for all MAC
alloBMTs. After 2006, PT/Cy (post-transplantation cyclophosphamide 50
mg/kg i.v. on days 3 and 4 after alloBMT) was used as sole GVHD prophylaxis
for MAC/HLA-identical alloBMTs. For RIC/HLA-identical alloBMTs, the GVHD
prophylaxis regimen was PT/Cy (days 3 and 4) with mycophenolate mofetil
15 mg/kg orally three times daily up to 1000 mg/dose given days 4 to
33 after transplantation. For RIC/haplo alloBMTs, the GVHD prophylaxis
regimen was PT/Cy (days 3 and 4), tacrolimus, and mycophenolate mofetil
(days 5 to 35). In the absence of GVHD, tacrolimus was continued with goal
trough of 5 to 15 ng/mL until day 180 after transplantation.Anaplastic large cell lymphoma, ALK positive 2
Anaplastic large cell lymphoma, ALK unknown 3
Extranodal 14 (32)
Enteropathy-associated T cell lymphoma 6
Hepatosplenic gamma-delta T cell lymphoma 6
Extranodal NK/T cell lymphoma, nasal type 1
Subcutaneous panniculitis-like gamma-delta T-cell 1
Other 7 (16)
Adult T cell leukemia/lymphoma 3
Mycosis fungoides 2
Cutaneous NK cell lymphoma 1
Blastic NK cell lymphoma 1
Remission status at alloBMT, n (%)
First partial or complete remission, without PIF 14 (32)
Second or greater remission, without PIF 8 (18)
Remission with history of PIF 11 (25)
Active disease at alloBMT 11 (25)
Prior chemotherapy resistance, n (%) 22 (50)
Number of prior therapies, n (%)
1 18 (40)
2 13 (30)
3 or more 13 (30)
Prior autologous BMT, n (%) 4 (9)
Years from diagnosis to alloBMT, median (range) .7 (.2-11)
Follow-up of survivors, yr, median (range) 3.9 (.5-13.7)
MAC 4.8 (.8-13.7)
RIC 1.9 (.5-5.1)
PIF indicates primary induction failure; ALK, anaplastic lymphoma kinase.Deﬁnitions of Disease Status and Clinical Outcomes
Primary induction failure (PIF) was deﬁned as progressive disease during
ﬁrst-line treatment or disease relapse within 2 months of treatment
completion. Chemoresistant disease was designated in patients with
primary induction failure or relapse refractory to salvage chemotherapy.
Disease status at the time of alloBMT was determined in accord with stan-
dard response criteria for non-Hodgkin lymphoma [13].
Neutrophil recovery time was the number of days from alloBMT to the
ﬁrst of 3 consecutive days with an absolute neutrophil count above 500/mL.
Platelet recovery time was the number of days from alloBMT to the ﬁrst day
with a platelet count of 20,000 without platelet transfusion in the
preceding week. Donor chimerism was determined by restriction fragment
length polymorphisms or polymerase chain reaction of variable nucleotide
tandem repeats. Full donor chimerismwas deﬁned as achievement of 95%
donor T cells in the blood at post-transplant day 30 or in the blood or bone
marrow at post-transplant day 60. Mixed chimerism was deﬁned as 5% to
94% donor cells. Primary graft failure was deﬁned as <5% donor cells by
posttransplant day 60. Day 60 engraftment was determined by donor
chimerism, if available, or count recovery criteria. Acute GVHD was graded
per the Keystone criteria, and chronic GVHD was graded per the 2005
National Institutes of Health Working Group Report and Seattle standard
guidelines [14-16].
Progression-free survival (PFS) was the time from alloBMT to disease
relapse, progression, or death from any cause. Overall survival (OS) was the
time from alloBMT to death from any cause. Nonrelapse mortality (NRM)
was deﬁned as death without disease relapse.Statistics
The dataset was locked for analysis on December 20, 2011. Descriptive
statistics were used to summarize baseline patient and alloBMT character-
istics and compared using the unpaired t test. The probabilities of PFS and OS
were estimated using the Kaplan-Meier method with 95% conﬁdence
intervals (CIs) and compared using the two-tailed Gehan-Wilcoxon test [17].
Cumulative incidences of relapse, NRM, and GVHD were estimated by
competing-risk analysis using Gray’s method [18]. Relapse and NRM were
competing risks for each other. Relapse, death, and graft failure were
competing risks for GVHD. An unadjusted landmark analysis setting day 18
(the median time to engraftment) as the landmark time was used to esti-
mate the cumulative incidence of relapse with respect to GVHD (acute
grades II-IV or chronic) as a time-dependent variable, treating NRM as
a competing risk for relapse [19]. Data were analyzed with the R program,
version 2.12 (R Core Development Team, Vienna, Austria).RESULTS
Table 1 presents patient characteristics. This was a poor-
risk cohort, with 60% receiving at least two prior chemo-
therapy regimens, 50% having history of chemorefractory
disease, and 25% having active disease at alloBMT. Table 2
presents transplantation characteristics. Donors were haplo
(n ¼ 22) or HLA-identical (n ¼ 22) ﬁrst-degree relatives.
Grafts in all but one case were marrow derived. Over two
thirds of alloBMTs (68%) incorporated high-dose PT/Cy for
GVHD prophylaxis, including all RIC alloBMTs (n ¼ 24). The
median follow-up for surviving patients was 3.9 years (range,
.5 to 13.7 years). At last follow-up, 16 of 44 patients were
alive, 15 without relapse. Overall, 32 of 36 assessable patients
(92%) engrafted by day 60; of the 4 that did not engraft, 3 had
autologous hematopoietic recovery and 1 received a second
marrow infusion with subsequent engraftment.Donor lymphocyte infusion (DLI) was used sparingly in
this cohort and was not given for mixed chimerism alone.
Decisions to pursue DLI in the setting of relapse were based
on the timing of relapse, GVHD history, and the use of haplo
versus HLA-matched grafts. Three patients did receive DLI. In
two cases, DLI was pre-emptively given within the 6 months
after myeloablative, HLA-matched alloBMT in patients
without GVHD and with very high-risk disease (hep-
atosplenic gamma-delta T cell lymphoma and blastic NK
lymphoma). Nonetheless, both patients died of relapsed
disease shortly after DLI. In the third case, DLI along with
involved ﬁeld radiation therapy was given to a patient with
disease relapse 4 years after RIC/haplo alloBMT, resulting in
ongoing disease-free survival at the time of data analysis.
The estimated 2-year PFS for all patients was 40% (95% CI,
26% to 55%) and OS was 43% (95% CI, 28% to 59%) (Figure 1A).
On unadjusted analysis, there was a tendency toward supe-
rior PFS for alloBMT in ﬁrst remission versus beyond ﬁrst
remission, with an estimated 2-year PFS of 53% (95% CI, 33%
to 77%) versus 29% (95% CI, 9% to 45%), P ¼ .08 (Figure 1B). Of
the 15 patients who remain alive in sustained remission, 10
received alloBMT in ﬁrst remission; represented among
these 10 are especially poor-risk histologies, including adult
T cell leukemia/lymphomas, hepatosplenic gamma-delta T
cell lymphoma, and subcutaneous panniculitis-like gamma-
delta T cell lymphoma.
To investigate other potential prognostic variables with
respect to survival outcomes, Kaplan-Meier curves were
constructed to compare outcomes for patients with nodal
Table 2
Transplantation Characteristics
Characteristic Result
Number of transplants 44
MAC 20
RIC 24
Transplant type, n (%)
RIC/HLA haploidentical 18 (41)
RIC/HLA identical 6 (14)
MAC/HLA identical 16 (36)
MAC/HLA haploidentical 4 (9)
HLA-haploidentical regimens, n (% of 22)
Flu/Cy/TBI with PT/Cy, tacrolimus, and MMF 18 (82)
Bu/Cy with PT/Cy, tacrolimus, and MMF 3 (14)
Cy/TBI with cyclosporine 1 (4)
HLA-matched regimens, n (% of 22)
Bu/Cy with cyclosporine 8 (36)
Cy/TBI with cyclosporine 5 (23)
Flu/TBI with PT/Cy and MMF 5 (23)
Bu/CY with PT/Cy alone 2 (9)
Bu/Flu with PT/Cy alone 1 (4)
Flu/Cy/TBI with PT/Cy, tacrolimus, and MMF 1 (4)
Donor relationship, n (%)
Sibling 35 (80)
Child 7 (16)
Parent 2 (4)
Unrelated 0
Donor age, yr, median (range) 47 (13-74)
Female donor and male recipient 10 (23)
Stem cell source, n (%)
Bone marrow, T cell replete 31 (70)
Bone marrow, T cell depleted 12 (27)
Peripheral blood, unprocessed 1 (2)
Graft dose, median (25th, 75th percentile)
Total nucleated cells  108/kg 3.25 (.6, 4.2)
CD34þ cells  106/kg 3.32 (2.5, 4.8)
CD3þ cells  107/kg 3.30 (.04, 3.9)
Days to count recovery, median (range)
Neutrophils (500/mL)
MAC (n ¼ 19) 18 (11-25)
RIC (n ¼ 20) 18 (13-28)
Platelets (20,000/mL)
MAC (n ¼ 16) 25 (18-43)
RIC (n ¼ 20) 24 (18-65)
Donor chimerism after RIC, n (%)
Day 30 (n ¼ 24)
Full (95% donor) 16 (67)
Mixed (5%-94% donor) 6 (25)
<5% donor 2 (8)
Day 60 (n ¼ 20)
Full 14 (70)
Mixed 4 (20)
<5% donor 2 (10)
MMF indicates mycophenolate mofetil.
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leukemic, and cutaneous), patients aged 60 versus
aged <60, and patients in remission at alloBMT versus those
with stable or progressive disease at transplant. No differ-
ences in PFS or OS estimates were found between groups for
any of these three variables. For exploratory purposes, an
unadjusted landmark analysis was performed to investigate
the relationship between GVHD and relapse. Overall,
patients with GVHD (acute grades II-IV or chronic) had
a lower probability of relapse of 17% (95% CI, 0% to 39%) than
patients without GVHD of 66% (95% CI, 48% to 84%), P ¼ .04.
Patients receiving RIC were older, with a median age of 59
years (range, 24 to 70), than patients receiving MAC, with
median age of 46 years (range, 18 to 64), P ¼ .01. The median
age at RIC/haplo alloBMTwas 60 years. In patients aged 60 or
older (n ¼ 14), the estimated 2-year PFS and OS were 38%
(95% CI, 18% to 79%) and 45% (95% CI, 24% to 86%), respec-
tively. This was similar to survival outcomes for patientsyounger than age 60 (n ¼ 30), with 2-year PFS and OS esti-
mates of 41% (95% CI, 27% to 64%) and 43% (95% CI, 28% to
66%), respectively. For MAC alloBMTs (n ¼ 20, 16 HLA-
identical), the estimated 2-year PFS and OS were 44% (95%
CI, 26% to 73%) and 42% (95% CI, 25% to 72%), respectively
(Figure 1C). For RIC alloBMTs (n ¼ 24, 18 haplo), 2-year
estimates of PFS and OS were 37% (95% CI, 21% to 65%) and
44% (95% CI, 26% to 72%), respectively (Figure 1D).
The estimated 1-year cumulative incidences of NRM
following alloBMT were 10% for patients receiving MAC (6%
for MAC/HLA-identical transplants) and 8% for patients
receiving RIC (11% for RIC/haplo transplants) (Figure 2).
Causes of NRM after MAC were GVHD (n ¼ 1), cardiac arrest
(n ¼ 1), multisystem failure (n ¼ 1), and donor-derived
lymphoma (n ¼ 1). Causes of NRM after RIC were GVHD
(n¼ 1), pulmonary embolism (n¼ 1), and stroke (n¼ 1). The
median time to relapse was 3.2 months (interquartile range,
1.8 to 8.8 months). The estimated 1-year cumulative inci-
dence of relapse after alloBMT was 40% for patients receiving
MAC (38% for MAC/HLA-identical transplants) and 38% for
patients receiving RIC (34% for RIC/haplo transplants)
(Figure 2). Only ﬁve relapses occurred beyond 1 year post-
alloBMT, with only two relapses occurring beyond 2 years
post-alloBMT and only one occurring beyond 3 years post-
alloBMT. Of note, three of the ﬁve late relapses were in
patients with enteropathy-associated T cell lymphoma
histology. Cumulative incidences of acute grade II-IV GVHD
and chronic GVHD were 16% and 19%, with no differences
between HLA-identical and haplo grafts.
DISCUSSION
We present nearly two decades of experience with
alloBMT for PTCL, in which two thirds of the patients
received RIC regimens, haplo grafts, or both. Our results
conﬁrm and extend the results of previous reports showing
long-term disease-free survival in a subset of patients with
PTCL after alloBMT [7-9,20-24].
If the efﬁcacy of alloBMT is due largely to both a GVL effect
and avoidance of graft contamination by tumor, then MAC
may not be a requisite in all cases. Although the median age
at PTCL diagnosis is 60 [25,26], the subset able to receive
MAC is most often two to three decades younger [20,24,27].
Utilization of RIC regimens has permitted alloBMT in older
and more heavily pretreated patients; indeed, the median
age at RIC/haplo alloBMT in this study was 60 years.
Although the potential for a GVL effect motivated the use
of alloBMT, GVHD and transplant-related mortality have
been major concerns. As in the treatment of other hemato-
logic malignancies [10,11,28,29], we report here that high-
dose PT/Cy for GVHD prophylaxis is associated with modest
and comparatively favorable rates of GVHD, even in recipi-
ents of haplo grafts [11]. This is the ﬁrst PTCL-restricted series
to include a substantial fraction of patients who received RIC/
haplo alloBMT, all of whom received high-dose PT/Cy as part
of their GVHD prophylaxis. The incidences of GVHD, relapse,
and NRM for RIC/haplo alloBMT in this series were compa-
rable with previous reports of outcomes after RIC/haplo
alloBMT with PT/Cy and furthermore closely approximate
the outcomes reported with RIC/HLA-identical platforms
[11,28,30-32]. Such alloBMT platforms may be ideally suited
for patients with PTCL, addressing the older age of this
patient population and concerns about treatment-related
toxicities.
There has been controversy with regard to the role and
optimal timing of alloBMT. Although reserving alloBMT for
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Figure 1. Kaplan-Meier survival estimates. (A) PFS (dashed line) and OS (solid line) for all patients (n ¼ 44). (B) PFS, stratiﬁed by remission. Patients receiving alloBMT
in ﬁrst remission (n ¼ 21, solid line) compared with patients receiving alloBMT beyond ﬁrst remission (n ¼ 23, dashed line), P ¼ .08. (C) PFS (dashed line) and OS (solid
line) for patients receiving MAC (n ¼ 20). (D) PFS (dashed line) and OS (solid line) for patients receiving RIC (n ¼ 24).
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who relapse are often resistant to salvage therapy. Both
alloBMT in ﬁrst remission and at relapse were represented in
this series, with remarkably favorable outcomes for alloBMT
in ﬁrst remission and very poor outcomes for those with
relapsed or refractory disease. The favorable outcomes for
patients transplanted in ﬁrst remission are notable consid-
ering the decision to proceed directly to alloBMT at ﬁrst
remission was typically reserved for patients with highly
unfavorable features, such as a history of primary induction
failure, central nervous system involvement, or very high-
risk histology, such as gamma-delta subtypes or adult T cell
leukemia/lymphoma. In a recently published prospective
study of upfront autologous BMT for PTCL patients in pure
ﬁrst remission, the estimated 5-year OS was 61% for those
receiving upfront autologous BMT, with PFS not reported for
this subgroup, but with an estimated 5-year PFS of 44% for
the intention-to-treat population [33]. In our series, patients
receiving alloBMT in ﬁrst remission, including those with
primary induction failure, had an estimated 5-year PFS of
54%, with an estimated 5-year OS also of 54%, comparing
favorably to the upfront autologous BMT outcomes, partic-
ularly considering that some of the alloBMT patients were
sparedMAC and that the rates of GVHD and NRMwere low in
this study. Given the retrospective nature of this study, it
remains uncertain if these ﬁrst remission BMT patientssimply had favorable disease biology and would have had
similar outcomes regardless of alloBMT, although this ﬁrst
remission cohort included aggressive subtypes with histori-
cally dismal outcomes, supporting a beneﬁt of early alloBMT
in select high-risk cases.
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and comparatively safe alloBMToption for the great majority
of PTCL patients, including older patients and thosewith only
partially HLA-matched donors. Given the poor outcomes for
relapsed PTCL patients both in this series and historically,
consolidation of ﬁrst remission with RIC/haplo alloBMT may
ultimately improve outcomes. Despite the increasing feasi-
bility and safety of alloBMT, disease relapse after transplant
continues to pose some limitations in the efﬁcacy of this
treatment modality for patients with PTCL. We found,
however, that most relapses occurred early in the post-
transplant course, adding further weight to the suggestion
of previous studies that the subset of PTCL patients with
long-term disease-free survival after alloBMTare likely cured
[7-9,20-24]. Approaches to alloBMT that are able to maxi-
mize the GVL effect while minimizing transplant-related
toxicities and GVHD are critical to improving outcomes in
these diseases. Although the retrospective nature of this
study and the heterogeneity of the lymphomas and their
treatment limit deﬁnitive conclusions, this study provides
evidence that there can be long-term disease free survival
after alloBMT for PTCL, even in older patients with partially
matched related donors. We hope that the ability to trans-
plant a much larger subset of PTCL patients will encourage
a cooperative group-based trial to prospectively evaluate the
role of alloBMT in the management of these patients.ACKNOWLEDGMENTS
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